These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 5094586)

  • 1. Reversal of resistance to methotrexate in L1210 murine leukemia by uracil.
    Wallerstein H; Slater LM; Eng B; Calman N
    Blood; 1971 Nov; 38(5):648-56. PubMed ID: 5094586
    [No Abstract]   [Full Text] [Related]  

  • 2. Immunologic heterogeneity of dihydrofolate reductase from methotrexate sensitive and resistant L1210 leukemia cells.
    Iqbal MP; Rothenberg SP; Larosa C
    Proc Soc Exp Biol Med; 1985 Oct; 180(1):98-102. PubMed ID: 2412235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The return of antimetabolite sensitivity in methotrexate- and 6-mercaptopurine-resistant L1210 murine leukemia by the process of adaptive selection.
    Wallerstein H; Slater LM; Eng B; Calman N
    Cancer Res; 1972 Oct; 32(10):2235-40. PubMed ID: 5080766
    [No Abstract]   [Full Text] [Related]  

  • 4. The intracellular concentration dependence of antifolate inhibition of DNA synthesis in L1210 leukemia cells.
    Sirotnak FM; Donsbach RC
    Cancer Res; 1974 Dec; 34(12):332-40. PubMed ID: 4429954
    [No Abstract]   [Full Text] [Related]  

  • 5. Antigenic changes associated with resistance to methotrexate and 6-mercaptopurine in L1210 ascites lymphoma.
    Calman NS; Eng B; Slater LM; Wallerstein H
    J Natl Cancer Inst; 1974 Mar; 52(3):997-8. PubMed ID: 4826575
    [No Abstract]   [Full Text] [Related]  

  • 6. Investigations on the mechanisms of methotrexate resistance in a cisplatin-resistant L1210 murine leukemia cell subline.
    Wroblewski DH; Bhushan A; Xuan Y; Brinton BT; Tritton TR; Hacker MP
    Cancer Chemother Pharmacol; 1996; 37(4):337-42. PubMed ID: 8548879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sites of action of amethopterin: intrinsic and acquired drug resistance.
    Harrap KR; Hill BT; Furness ME; Hart LI
    Ann N Y Acad Sci; 1971 Nov; 186():312-24. PubMed ID: 5289423
    [No Abstract]   [Full Text] [Related]  

  • 8. Sequential biochemical alteration to antifolate resistance in L1210 leukaemia.
    Sirotnak FM; Kurita S; Sargent MG; Robinson DL; Hutchison DJ
    Nature; 1967 Dec; 216(5121):1236-7. PubMed ID: 5235641
    [No Abstract]   [Full Text] [Related]  

  • 9. The basis for the disparate sensitivity of L1210 leukemia and Walker 256 carcinoma to a new triazine folate antagonist.
    Skeel RT; Sawicki WL; Cashmore AR; Bertino JR
    Cancer Res; 1973 Nov; 33(11):2972-6. PubMed ID: 4748449
    [No Abstract]   [Full Text] [Related]  

  • 10. Antifolate resistance and the genetic control of dihydrofolate reductase activity.
    Hutchison DJ
    Ann N Y Acad Sci; 1971 Nov; 186():172-81. PubMed ID: 4399850
    [No Abstract]   [Full Text] [Related]  

  • 11. Limited effectiveness of in vitro high-dose methotrexate and leucovorin to overcome resistance in L1210 leukemia cells with elevations of dihydrofolate reductase.
    Bruckner H; Rubinoff M; Waxman S
    Eur J Cancer (1965); 1980 Aug; 16(8):1057-63. PubMed ID: 6969180
    [No Abstract]   [Full Text] [Related]  

  • 12. Differential cell permeability and the basis for selective activity of methotrexate during therapy of the L1210 leukemia.
    Sirotnak FM; Donsbach RC
    Cancer Res; 1973 Jun; 33(6):1290-4. PubMed ID: 4718678
    [No Abstract]   [Full Text] [Related]  

  • 13. Substrate and inhibitor complexes of dihydrofolate reductase from amethopterin-resistant L1210 cells.
    Neef VG; Huennekens FM
    Arch Biochem Biophys; 1975 Dec; 171(2):435-43. PubMed ID: 959
    [No Abstract]   [Full Text] [Related]  

  • 14. The metabolic fate of tritiated methotrexate. I. Absorption, excretion, and distribution in mice, rats, dogs and monkeys.
    Henderson ES; Adamson RH; Denham C; Oliverio VT
    Cancer Res; 1965 Aug; 25(7):1008-17. PubMed ID: 4954195
    [No Abstract]   [Full Text] [Related]  

  • 15. Dihydrofolate reductase activity of leukemia L1210 during development of methotrexate resistance.
    Schrecker AW; Mead JA; Greenberg NH; Goldin A
    Biochem Pharmacol; 1971 Mar; 20(3):716-8. PubMed ID: 5150168
    [No Abstract]   [Full Text] [Related]  

  • 16. Methotrexate resistance in an in vivo mouse tumor due to a non-active-site dihydrofolate reductase mutation.
    Dicker AP; Waltham MC; Volkenandt M; Schweitzer BI; Otter GM; Schmid FA; Sirotnak FM; Bertino JR
    Proc Natl Acad Sci U S A; 1993 Dec; 90(24):11797-801. PubMed ID: 8265628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of methotrexate responsiveness of tumors in man.
    Bertino JR; Hryniuk WM; Capizzi R
    Natl Cancer Inst Monogr; 1971 Dec; 34():179. PubMed ID: 5291100
    [No Abstract]   [Full Text] [Related]  

  • 18. Some biochemical characteristics of L1210 cell lines resistant to 6-mercaptopurine and 6-thioguanine and with increased sensitivity to methotrexate.
    Strobel-Stevens JD; El Dareer SM; Trader MW; Hill DL
    Biochem Pharmacol; 1982 Oct; 31(19):3133-7. PubMed ID: 6890814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of free and carrier-bound methotrexate against transport-deficient and high dihydrofolate dehydrogenase-containing methotrexate-resistant L1210 cells.
    Chu BC; Fan CC; Howell SB
    J Natl Cancer Inst; 1981 Jan; 66(1):121-4. PubMed ID: 6935452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of intracellular conversion of dihydrohomofolate to tetrahydrohomofolate in leukemia cells with high levels of dihydrofolate reductase.
    Nahas A; Friedkin M
    Mol Pharmacol; 1972 May; 8(3):353-61. PubMed ID: 5040933
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.